Table 1.
General characteristics of the patients included in the futile recanalization and meaningful recanalization groups.
| FR (n = 129) | MR (n = 109) | p | |
|---|---|---|---|
| Demographic data | |||
| Age, years* | 79 (71–83) | 72 (63.2–78) | 0.001 |
| Females, n (%) | 76 (58.9) | 50 (45.9) | 0.045 |
| Vascular risk factors | |||
| Previous transient ischemic attack/stroke, n (%) | 12 (9.3) | 13 (11.9) | 0.511 |
| Cardiovascular disease, n (%) | 16 (12.4) | 19 (17.4) | 0.275 |
| Atrial fibrillation, n (%) | 41 (31.8) | 24 (22) | 0.092 |
| Hypertension, n (%) | 94 (72.9) | 67 (61.5) | 0.061 |
| Diabetes mellitus, n (%) | 19 (14.7) | 14 (12.8) | 0.675 |
| Hypercholesterolemia, n (%) | 34 (26.4) | 28 (25.7) | 0.907 |
| Current smoking, n (%) | 15 (12.4) | 21 (20.2) | 0.112 |
| Previous antithrombotic treatment | 0.488 | ||
| Antiplatelets, n (%) | 32 (24.8) | 27 (24.8) | |
| Anticoagulants, n (%) | 25 (19.4) | 15 (13.8) | |
| Systolic blood pressure at admission, mmHg | 152.6 ± 24.6 | 149.6 ± 21.6 | 0.387 |
| Laboratory findings | |||
| Hb, g/dl* | 12.2 (11–13.9) | 12 (13–14) | 0.072 |
| Platelets, 103/mmc* | 188 (150–232.7) | 202 (162–251) | 0.076 |
| aPTT ratio | 1.03 ± 0.22 | 0.99 ± 0.16 | 0.145 |
| INR | 1.11 ± 0.21 | 1.05 ± 0.17 | 0.041 |
| Creatinine, mg/dl* | 0.92 (0.73–1.12) | 0.84 (0.76–1.06) | 0.297 |
| C-reactive protein, mg/l* | 10.05 (3.86–23.26) | 6 (2.1–12.45) | 0.002 |
| Fasting glucose, mg/dl* | 113 (98.8–147) | 98 (89–112) | 0.001 |
| HbA1c values, %* | 5.9 (5.5–6.3) | 5.7 (5.4–6) | 0.030 |
| GAR index* | 19.6 (17.4–23.2) | 17.6 (15.6–19.8) | 0.001 |
| Total cholesterol, mg/dl | 160.7 ± 35.7 | 166.2 ± 38.8 | 0.271 |
| HDL cholesterol, mg/dl* | 51 (39.5–59) | 51 (42–62) | 0.549 |
| LDL cholesterol, mg/dl | 90.3 ± 30.9 | 94.6 ± 33.6 | 0.323 |
| Triglycerides, mg/dl* | 87.5 (71.2–133) | 93 (69–131) | 0.958 |
| Previous antithrombotic treatment | 0.488 | ||
| Antiplatelets, n (%) | 32 (24.8) | 27 (24.8) | |
| Anticoagulants, n (%) | 25 (19.4) | 15 (13.8) | |
| Stroke subtypes based on TOAST classification | 0.613 | ||
| Large arterial atherosclerosis, n (%) | 13 (10.1) | 17 (15.5) | |
| Cardioembolism, n (%) | 76 (58.9) | 58 (53.2) | |
| Other determined etiology, n (%) | 9 (7) | 7 (6.4) | |
| Undetermined etiology, n (%) | 31 (24) | 27 (24.8) | |
| Baseline clinical characteristics | |||
| NIHSS score at admission, median (IQR) | 18 (16–21) | 14 (10–18) | 0.001 |
| Pre-stroke mRS 0–2, n (%) | 118 (91.5) | 105 (96.3) | 0.124 |
| Baseline ASPECTS, median (range) | 10 (6–10) | 10 (7–10) | 0.001 |
| Presence of SICH, n (%) | 17 (13.2) | 3 (2.9) | 0.004 |
FR, futile recanalization; MR, meaningful recanalization; Hb, hemoglobin; aPTT, activated partial thromboplastin time; INR, international normalized ratio; HbA1C, glycated hemoglobin; GAR, glucose-to-glycated hemoglobin ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin scale; ASPECTS, Alberta Stroke Program Early CT Score; SICH, symptomatic intracranial hemorrhage. Data are presented as mean and standard deviation for normally distributed continuous variables. Non-normally distributed continuous variables are displayed as median and interquartile range and are identified by an asterisk (*). Bold values denote statistical significance at a p-value of < 0.05.